Healthcare ETFs are having a moment again, and this time the catalyst is a familiar villain: uncertainty around Medicare Advantage payment rates. When UnitedHealth Group Inc (UNH) reported mixed earnings recently, it became crystal clear why putting all your eggs in the managed care basket might not be the smartest move right now.

Rather than bailing on healthcare entirely, investors are gravitating toward broad-based healthcare ETFs that spread the risk around. Think of it as the financial equivalent of not betting your entire retirement on one horse at the track, especially when that horse is subject to government payment schedules.

These ETFs balance exposure to healthcare insurers with pharmaceutical companies, biotech firms, and medical technology stocks. Each of these segments operates on completely different regulatory and earnings cycles, which is exactly the point when one segment is getting squeezed.

How ETFs Create a Buffer Against Policy Whiplash

The Vanguard Health Care ETF (VHT) and State Street Health Care Select Sector SPDR ETF (XLV) both offer diversified portfolios across the healthcare landscape. Sure, they hold managed care stocks, but their portfolios are heavily weighted toward pharmaceutical giants like Eli Lilly And Co (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV). These companies operate in a different universe when it comes to Medicare Advantage payment rates—their revenues depend more on blockbuster drugs and innovation cycles than government reimbursement schedules.

If you want to go even further away from reimbursement risk, there's the iShares U.S. Pharmaceuticals ETF (IHE), which cuts insurers out of the picture entirely. It focuses exclusively on pharmaceutical companies whose revenues are tied to product development, market demand, and patent cycles rather than whatever CMS decides to pay this year.

The strategy here is straightforward: maintain your healthcare sector exposure while hedging against the regulatory curveballs that can hammer individual subsectors.

Why Medicare Advantage Is Causing Headaches Again

The renewed focus on healthcare ETFs follows a policy announcement from the U.S. Centers for Medicare & Medicaid Services that Medicare Advantage reimbursement rates would essentially flatline next year. The Trump administration revealed an average increase of just 0.09% for 2027. Analysts had been expecting something in the 4% to 6% range. That's not a rounding error—that's a fundamental mismatch between expectations and reality.

Here's the problem: the federal government sets these reimbursement rates, and insurers have limited levers to pull when rates stop growing but medical and administrative costs keep climbing. This makes profitability extremely vulnerable to cost inflation, turning every policy decision into a potential earnings catalyst—and not necessarily the good kind.

UnitedHealth's Numbers Tell the Story

UnitedHealth was the first major managed care insurer to report earnings this season, and its results provided a real-world illustration of the margin squeeze everyone's been worried about.

The company posted fourth-quarter 2025 adjusted earnings of $2.11 per share, down dramatically from $6.81 a year ago, though it did manage to slightly beat consensus. Revenue climbed 12% year-over-year to $113.2 billion but still missed analyst estimates.

The more telling detail was UnitedHealth's medical care ratio, which hit 89.1% for fiscal 2025. That's up 340 basis points from the prior year, with the fourth-quarter MCR reaching 92.4%. In plain English, an increasingly large chunk of premium dollars is going straight to medical care costs. That's exactly the nightmare scenario when reimbursement growth grinds to a halt.

UnitedHealth Group emphasized its disciplined cost management and projected modest margin improvement for 2026. But the company's revenue guidance came in below consensus, reinforcing concerns that the reimbursement squeeze could limit top-line growth going forward.

What Comes Next

While UnitedHealth Group's diversified business model provides some insulation, its earnings report has effectively set the benchmark for the rest of the industry. Eyes are now turning to Humana Inc (HUM) and CVS Health Corp (CVS), both of which have substantial Medicare Advantage exposure. Their stocks have been in free fall since Tuesday, and both companies are scheduled to report earnings in February. Investors will be watching closely for similar margin pressure trends.

Until there's more clarity on the reimbursement policy front, healthcare ETFs look like a sensible middle path. They offer exposure to the long-term growth trajectory of the healthcare industry without leaving you overly vulnerable to policy shifts that can upend individual subsectors overnight. Sometimes the boring, diversified approach turns out to be the smart play after all.